person · Reporting owner
Stauffer Joseph William
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Chief Medical Officer | October 17, 2018 | October 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date October 17, 2018 · Filed October 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,000 |
Ending reported balance
After 2018-10-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-10-17 · Sale · Disposed 10,472 · Balance 2,970 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.60 - $20.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Row 2 · 2018-10-17 · Sale · Disposed 970 · Balance 2,000 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.60 - $20.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.60 - $20.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.60 - $20.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2018 Filed Oct 19, 2018 16:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 970 | $20.69 | $20,069.30 |
DisclosureSEC source: 0001209191-18-055688 · doc4.xml · nonDerivative · entry 2 Stauffer Joseph William · CIK 0001466459 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.60 - $20.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 16:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 10,472 | $20.08 | $210,277.76 |
DisclosureSEC source: 0001209191-18-055688 · doc4.xml · nonDerivative · entry 1 Stauffer Joseph William · CIK 0001466459 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,970 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.60 - $20.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:37 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 57,750 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001209191-18-019405 · doc4.xml · derivative · entry 1 Stauffer Joseph William · CIK 0001466459 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Stock · 57,750 shares Expires 2028-03-09 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 9, 2018, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 17:18 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $17.41 | $0.00 |
DisclosureSEC source: 0001209191-17-019913 · doc4.xml · derivative · entry 1 Stauffer Joseph William · CIK 0001466459 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-08 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.